S. Kakar

Biosimilars

Harry Yang, H. Gutka, S. Kakar, 2018, AAPS Advances in the Pharmaceutical Sciences Series.

A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status

Benjamin Izar, K. Flaherty, R. Dummer, 2017, Cancer medicine.

6′7′‐Dihydroxybergamottin Contributes to the Grapefruit Juice Effect

P. Watkins, P. Stewart, M. Paine, 2004, Clinical pharmacology and therapeutics.

Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to support Drug Product Quality: A Workshop Summary Report.

Gustavo Mendes Lima Santos, J. Dressman, A. Babiskin, 2020, Journal of pharmaceutical sciences.

Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor

G. Caponigro, Nanxin Li, Edward G. Lorenzana, 2012 .

Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.

Tracey Clark, Matthew D. Wessel, R. D. Connell, 2013, Bioorganic & medicinal chemistry letters.

Design of selective, ATP-competitive inhibitors of Akt.

Tracey Clark, Matthew Marx, Blaise Lippa, 2010, Journal of medicinal chemistry.

Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches

Bill J Smith, T. Maurer, K. Beaumont, 2009, Journal of clinical pharmacology.

Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma.

K. Flaherty, R. Dummer, M. Atkins, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Synthesis and structure based optimization of novel Akt inhibitors.

Tracey Clark, Blaise Lippa, J. Pandit, 2008, Bioorganic & medicinal chemistry letters.